Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high ...
InvestorsHub on MSN
CytomX highlights clinical progress for lead cancer drug in Q4 update
CytomX Therapeutics Inc. (NASDAQ:CTMX) used its fourth-quarter 2025 earnings call to highlight progress in the clinical ...
A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...
Cancer drug in development at Ohio State could treat some of the most difficult forms of the illness
This weekend, thousands of riders will take to the streets for Pelotonia — the annual bike ride that raises millions of dollars for cancer research right here in Columbus. One of the projects ...
Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high ...
The new reaction enables selective modification of anti-cancer drugs, rapid synthesis of medicinal compounds, and production ...
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...
Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 ...
Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...
This activity was supported by Contract No. 200-2011-38807 (Task Order No. 0051) and Contract No. HHSN263201200074I (Task Order No. HHSN26300052) with the Centers for Disease Control and Prevention ...
CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results